We thus hypothesized that PAD2 contributes to the pathogenesis of RA-ILD by inducing a profibrotic phenotype in fibroblasts that is abrogated by SDC2 via CD148-dependent inhibition of PI3K/Akt/Sp1 signaling. Here, PTPRJ is linked to rheumatoid arthritis.